



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q2FY22 results

Mumbai, 12th November, 2021: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the second quarter ending 30th September, 2021.

Consolidated Q2FY22 and H1FY22 FDC reported:

Rs. in lakhs	Q2' 21-22	Q2' 20-21	YOY Growth %
Operating Revenues	39,762	37,139	7%
EBITDA	10,159	12,476	-19%
EBITDA %	26%	34%	-24%
PBT	9,137	11,429	-20%
PAT	7,232	8,808	-18%
EPS	4.28	5.15	-17%

Rs. in lakhs	H1' 21-22	H1' 20-21	YOY Growth %
Operating Revenues	84,509	67,957	24%
EBITDA	24,026	25,631	-6%
EBITDA %	28%	38%	-25%
PBT	21,967	23,565	-7%
PAT	17,016	17,980	-5%
EPS	10.08	10.52	-4%

Commenting on the results;

We saw good growth in our Domestic business, which is a big part of our overall business. This was driven by robust demand across our established therapies and brands leading to 45% revenue growth. Our USA business portfolio saw some price erosion and lower demand for current portfolio due to re-entry of competitors, still our partner has been successful in maintaining good portion of market share.

Overall our sales has increased over last year same period, the profits had some hit because of increases in RM prices, increase in freight cost and reduction in profit share from US market.

India Market:

Sale of branded formulations in India for Q2FY22 was Rs.34,684 lakhs, a growth of 26% over the same quarter last year. Overall sales in India markets accounted for 88% of total consolidated sales for the quarter. For the first half, Branded sales formulations were at Rs. 73,530 lakhs, growth of 45% over the same period last year.

CORPORATE OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102, INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad, INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176



As per secondary sales data by IQVIA for the half year ended Sept 30, 2021, the Company delivered a strong YoY growth of 29% compared to Indian Pharmaceutical Market (IPM) growth of 26% YoY. This growth was mainly driven by Big brands such as Zifi, Electral and Enerzal which witnessed a good volume growth.

Export Formulations Market:

Formulation Sales in the Export market were Rs.3,598 lakhs in Q2FY22, down by 54% over Q2 last year and accounted for 9% of total consolidated sales. For first half sales were Rs. 7,910 lakhs, down by 42% over same period last year.

Export API Market:

API Sales in the Export market were Rs. 1,324 lakhs in Q2FY22, down by 4% over Q2 last year and accounted for 3% of total consolidated sales. For the first half, sales were Rs. 2,714 lakhs, down by 7% over first half last year.

ABOUT FDC LTD

Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmic. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

